Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Caplyta
Pharma
J&J acquires CNS specialist Intra-Cellular for $14.6B
J&J has bought out Intra-Cellular Therapies for $14.6 billion. The New York biotech develops and markets products for the central nervous system.
Kevin Dunleavy
Jan 13, 2025 10:29am
Intra-Cellular's unstoppable Caplyta nails another trial
Nov 5, 2024 10:15am
Intra-Cellular closing in on major depression nod for Caplyta
Jun 18, 2024 11:40am
Intra-Cellular moves closer to Caplyta depression expansion
Apr 16, 2024 2:27pm
Intra-Cellular re-ups winning ad as bipolar drug builds momentum
Aug 8, 2023 12:51pm
Method for the Madness: Intra-Cellular and GSK talk drug ads
Apr 18, 2023 9:40am
